Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Holly Lee

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
Ebiomedicine|July 2, 2022
Prenatal treprostinil reduces the pulmonary hypertension phenotype in the rat model of congenital diaphragmatic herniaFelix Rafael De Bie, Christopher Gates Halline, Travis Kotzur, et al.
Blood|September 25, 2024
Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myelomaHolly Lee, Michael Durante, Sheri Skerget, et al.
Blood Advances|July 8, 2026
TNFRSF17 genomic profiling guides retreatment with alternative BCMA-directed immunotherapies in multiple myelomaBenjamin Podvin, Holly Lee, Remi Tilmont, et al.
Cancer Cell|March 10, 2023
The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patientsMirco J Friedrich, Paola Neri, Niklas Kehl, et al.
Blood Cancer Discovery|November 7, 2023
ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple MyelomaPaola Neri, Benjamin G Barwick, David Jung, et al.
Journal of Hematology & Oncology|November 14, 2025
B7-H3 nanobody-based CAR T cells control multiple myeloma growth, while dual BCMA/B7-H3 CAR T cells overcome antigen escapeArne Van der Vreken, Fien Meeus, Chenggong Tu, et al.
Blood|June 10, 2025
Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myelomaBenjamin T Diamond, Linda B Baughn, Mansour Poorebrahim, et al.
Nature Medicine|August 31, 2023
Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myelomaHolly Lee, Sungwoo Ahn, Ranjan Maity, et al.
Nature Medicine|January 15, 2026
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myelomaHolly Lee, Sungwoo Ahn, Gerone A Gonzales, et al.
Biorxiv : the Preprint Server for Biology|December 19, 2025
Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myelomaFrancesco Maura, Ciara L Freeman, Kylee H Maclachlan, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
Ebiomedicine|July 2, 2022
Prenatal treprostinil reduces the pulmonary hypertension phenotype in the rat model of congenital diaphragmatic herniaFelix Rafael De Bie, Christopher Gates Halline, Travis Kotzur, et al.
Blood|September 25, 2024
Impact of soluble BCMA and non-T-cell factors on refractoriness to BCMA-targeting T-cell engagers in multiple myelomaHolly Lee, Michael Durante, Sheri Skerget, et al.
Blood Advances|July 8, 2026
TNFRSF17 genomic profiling guides retreatment with alternative BCMA-directed immunotherapies in multiple myelomaBenjamin Podvin, Holly Lee, Remi Tilmont, et al.
Cancer Cell|March 10, 2023
The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patientsMirco J Friedrich, Paola Neri, Niklas Kehl, et al.
Blood Cancer Discovery|November 7, 2023
ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple MyelomaPaola Neri, Benjamin G Barwick, David Jung, et al.
Journal of Hematology & Oncology|November 14, 2025
B7-H3 nanobody-based CAR T cells control multiple myeloma growth, while dual BCMA/B7-H3 CAR T cells overcome antigen escapeArne Van der Vreken, Fien Meeus, Chenggong Tu, et al.
Blood|June 10, 2025
Biallelic antigen escape is a mechanism of resistance to anti-CD38 antibodies in multiple myelomaBenjamin T Diamond, Linda B Baughn, Mansour Poorebrahim, et al.
Nature Medicine|August 31, 2023
Mechanisms of antigen escape from BCMA- or GPRC5D-targeted immunotherapies in multiple myelomaHolly Lee, Sungwoo Ahn, Ranjan Maity, et al.
Nature Medicine|January 15, 2026
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myelomaHolly Lee, Sungwoo Ahn, Gerone A Gonzales, et al.
Biorxiv : the Preprint Server for Biology|December 19, 2025
Plasma cell identity escape drives resistance to anti-BCMA T-cell-redirecting therapy in multiple myelomaFrancesco Maura, Ciara L Freeman, Kylee H Maclachlan, et al.
Pageof 5